Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases
Claire Larramendy-Gozalo(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Jean‐Philippe Deslys(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Estelle Daudigeos(Inserm), Emmanuel Petit(Centre National de la Recherche Scientifique), Dulce Papy-García(Université Paris-Est Créteil), Denis Barritault(Délégation Paris 7), Agnès Barret(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Lucie Antonangeli(Commissariat à l'Énergie Atomique et aux Énergies Alternatives), Émilie Mathieu(Simon Fraser University), Paul Brown(National Institute of Neurological Disorders and Stroke), Cécile Riffet(Centre National de la Recherche Scientifique)
Cited by 43
Related Papers
Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects
|Annals of Neurology|1999|1.4k
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
|Proceedings of the National Academy of Sciences|2013|864
Heparan Sulfate Is a Cellular Receptor for Purified Infectious Prions
|Journal of Biological Chemistry|2005|175
New Insight into Abnormal Prion Protein Using Monoclonal Antibodies
|Biochemical and Biophysical Research Communications|1999|143
The 37‐kDa/67‐kDa Laminin Receptor Acts as a Receptor for Infectious Prions and Is Inhibited by Polysulfated Glycanes
|The Journal of Infectious Diseases|2006|126